582 related articles for article (PubMed ID: 27609708)
41. Do persons with diabetes benefit from combination statin and fibrate therapy?
Rosenblit PD
Curr Cardiol Rep; 2012 Feb; 14(1):112-24. PubMed ID: 22213157
[TBL] [Abstract][Full Text] [Related]
42. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
[TBL] [Abstract][Full Text] [Related]
43. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels.
Makariou SE; Liberopoulos EN; Agouridis AP; Challa A; Elisaf M
J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):382-6. PubMed ID: 22431864
[TBL] [Abstract][Full Text] [Related]
44. Benefits and risks of the treatment with fibrates--a comprehensive summary.
Okopień B; Bułdak Ł; Bołdys A
Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1099-1112. PubMed ID: 30328735
[TBL] [Abstract][Full Text] [Related]
45. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
Jialal I; Smith G
Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
[No Abstract] [Full Text] [Related]
46. [Expediency of the use of fibrates for primary and secondary prevention of cardiovascular complications.].
Mamedov MN
Kardiologiia; 2006; 46(12):39-47. PubMed ID: 17310961
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
[TBL] [Abstract][Full Text] [Related]
48. More clinical lessons from the FIELD study.
Fazio S
Cardiovasc Drugs Ther; 2009 Jun; 23(3):235-41. PubMed ID: 19160032
[TBL] [Abstract][Full Text] [Related]
49. [Multimodal therapy of dyslipidemia].
Stahn A; Hanefeld M
Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
[TBL] [Abstract][Full Text] [Related]
50. CODAP: A multidisciplinary consensus among Portuguese experts on the definition, detection and management of atherogenic dyslipidemia.
Mello E Silva A; Aguiar C; Sequeira Duarte J; Couto L; Teixeira Veríssimo M; Marques da Silva P
Rev Port Cardiol (Engl Ed); 2019 Aug; 38(8):531-542. PubMed ID: 31447268
[TBL] [Abstract][Full Text] [Related]
51. A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Steiner G
Treat Endocrinol; 2005; 4(5):311-7. PubMed ID: 16185099
[TBL] [Abstract][Full Text] [Related]
52. [Gastroenterological aspects of atherosclerosis].
Zvenigorodskaia LA; Samsonova NG; Efremov LI; Cherkashova EA; Lazebnik LB
Eksp Klin Gastroenterol; 2011; (2):31-6. PubMed ID: 21560640
[TBL] [Abstract][Full Text] [Related]
53. The role of fibrate treatment in dyslipidemia: an overview.
Katsiki N; Nikolic D; Montalto G; Banach M; Mikhailidis DP; Rizzo M
Curr Pharm Des; 2013; 19(17):3124-31. PubMed ID: 23317397
[TBL] [Abstract][Full Text] [Related]
54. Fibrates in the management of atherogenic dyslipidemia.
Okopień B; Buldak L; Bołdys A
Expert Rev Cardiovasc Ther; 2017 Dec; 15(12):913-921. PubMed ID: 29183206
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
Harivenkatesh N; David DC; Haribalaji N; Sudhakar MK
J Cardiovasc Pharmacol Ther; 2014 May; 19(3):296-303. PubMed ID: 24516261
[TBL] [Abstract][Full Text] [Related]
56. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
57. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Geng Q; Ren J; Chen H; Lee C; Liang W
Curr Med Res Opin; 2013 Mar; 29(3):181-8. PubMed ID: 23323878
[TBL] [Abstract][Full Text] [Related]
58. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Kei A; Tellis C; Liberopoulos E; Tselepis A; Elisaf M
Cardiovasc Ther; 2014 Aug; 32(4):139-46. PubMed ID: 24618208
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
60. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis.
Choi HD; Shin WG; Lee JY; Kang BC
Vascul Pharmacol; 2015; 65-66():23-30. PubMed ID: 25451563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
